Twenty years of non-peptide CCK1 receptor antagonists: All that glitters is not gold

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 9, 2006, Pages 1193-1213

  Lassiani, Lucia ^a   Varnavas, Anthony ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Antagonists; CCK; CCK1; CCKA; Cholecystokinin; Drug applications

Indexed keywords

1,4 THIENODIAZEPINE DERIVATIVE; 2 NAPHTHALENESULFONYL 1 ASPARTYL (2 PHENETHYL)AMIDE; ALPHA METHYL N [(TRICYCLO[3.3.1.1 3,7]DEC 2 YLOXY)CARBONYL]TRYPTOPHYL DEXTRO 3 BENZYL BETA ALANINE; ANTHRANILIC ACID DERIVATIVE; ARGINIUM 4 [N (3 METHOXYPROPYL) N PENTYLCARBAMOYL] 5 (2 NAPHTHYLSULFONYL)PENTANOATE; ASPERLICIN; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEVAZEPIDE; DEXLOXIGLUMIDE; DIAZEPAM; FR 120480; INDOLE DERIVATIVE; IQM 95333; L 743345; LINTITRIPT; LORGLUMIDE; LOXIGLUMIDE; LY 294920; N [1 (2 FLUOROPHENYL) 3,4,6,7 TETRAHYDRO 4 OXOPYRROLO[3,2,1 JK][1,4]BENZODIAZEPIN 3 YL] 1H INDOLE 2 CARBOXAMIDE; PEPTOID; PLACEBO; PROGLUMIDE; PYRAZOLE DERIVATIVE; SC 50998; T 0632; TARAZEPIDE; TP 680; UNCLASSIFIED DRUG; UNINDEXED DRUG; VL 0395;

BILIARY TRACT DISEASE; BINDING AFFINITY; BINDING SITE; CHEMICAL MODIFICATION; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL RESEARCH; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG DESIGN; DRUG EXCRETION; DRUG IDENTIFICATION; DRUG INDICATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENZYME INHIBITION; ENZYME SYNTHESIS; FEEDING DISORDER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HUMAN; IRRITABLE COLON; NONHUMAN; PANCREAS DISEASE; PATENT; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; STOMACH PARESIS; STRUCTURE ACTIVITY RELATION;

EID: 33748680299     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.9.1193     Document Type: Review

References (109)

1. WILLIAMS JA: Cholecystokinin: a hormone and neurotransmitter. Biomed. Res. (1982) 3:107-115.
2. DOUGLAS BR, JANSEN JB, DE JONG AJ et al.: Effect of various triglycerides on plasma cholecystokinin levels in rats. J Nutr. (1990) 120:686-690.
3. LEWIS LD, WILLIAMS JA: Regulation of cholecystokinin secretion by food, hormones, and neural pathways in the rat. Am. J. Physiol. (1990) 258:G512-G518.
4. SCHWARTZ GJ, MORAN TH, WHITE WO et al.: Relationships between gastric motility and gastric vagal afferent responses to CCK and GRP in rats differ. Am. J Physiol (1997) 272:R1726-R1733.
5. CRIDER JR: Role of cholecystokinin in the regulation of gastrointestinal motility. J. Nutr. (1994) 124:1334S-1339S.
6. WANK SA. G-protein-coupled receptors in gastrointestinal physiology 1. CCK receptors: An exemplary family. Am. J Physiol (1998) 274:G607-G613.
7. DEGEN L, MATZINGER D, DREWE J et al: The effect of cholecystokinin in controlling appetite and food intake in humans. Peptides (2001) 22:1265-1269.
8. WIESENFELD-HALLIN Z, XU XJ: The role of cholecystokinin in nociception, neuropathic pain and opiate tolerance. Regul. Pept. (1996) 65:23-28.
9. SZELENYI Z: Cholecystokinin and thermoregulation: a mini review. Peptides (2001) 22:1245-1250.
10. GRIEBEL G: Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther. (1999) 82:1-61.
11. REHFELD JF: Cholecystokinin and panic disorder: three unsettled questions. Regul. Pept. (2000) 93:79-83.
12. VILLANUEVA ML, COLLINS SM, JENSEN RT et al.: Structural requirements for action of cholecystokinin on enzyme secretion from pancreatic acini. Am. J. Physiol. (1982) 242:G416-G422.
13. DESCHENES RJ, LORENZ LJ, HAUN RS et al.: Cloning and sequence analysis of a cDNA encoding rat pre-procholecystokinin. Proc. Natl. Acad. Sci. USA (1984) 81:726-730
14. INNIS RB, SNYDER SH: Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. USA (1980) 77:6917-6912.
15. NOBLE F, WANK SA, CRAWLEY JN et al.: International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol. Rev. (1999) 51:745-781.
16. PISEGNA JR, DEWEERTH A, HUPPI K et al: Molecular cloning, functional expression, and chromosomal localization of the human cholecystokinin type A receptor. Ann. N. Y. Acad. Sci. (1994) 713:338-342.
17. LEE YM, BEINBORN M, McBRIDE EW et al.: The human brain cholecystokinin-B/ gastrin receptor. Cloning and characterization. J. Biol. Chem. (1993) 268:8164-8169.
18. DUNLOP J: CCK receptor antagonists. Gen. Pharmac. (1998) 31:519-524.
19. DE TULLIO P, DELARGE J, PIROTTE B: Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). Curr. Med. Chem. (1999) 6:433-455.
20. HERRANZ R: Cholecystokinin antagonists: pharmacological and therapeutic potential. Med. Res. Rev. (2003) 23:559-605.
21. HILL DR, CAMPBELL NJ, SHAW TM et al.: Autoradiographic localisation and biochemical characterisation of peripheral type CCK receptors in rat CNS using highly selective non-peptide CCK antagonists. J. Neurosci. (1987) 7:2967-2976.
22. WOODRUFF GN, HILL DR, BODEN P et al.: Functional role of brain CCK receptors. Neuropeptides (1991) 19(Suppl.):45-56.
23. WANK SA. Cholecystokinin receptors. Am. J. Physiol. (1995) 269:G628-G646.
24. FELICIANO LF, MAZZINI BK, CACHEIRO RG et al.: Stimulation of either cholecystokinin receptor subtype reduces while antagonists potentiate or sensitize a morphine-induced excitatory response. Peptides (2001) 22:1299-1304.
25. CRAWLEYJN: Cholecystokinin-dopamine interactions. Trends Pharmacol. Sci. (1991) 12:232-236.
26. WANK SA, HARKINS R, JENSEN RT et al.: Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc. Natl. Acad. Sci. USA (1992) 89:3125-3129.
27. DE WEERTH A, PISEGNA JR, HUPPI K et al.: Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor. Biochem. Biophys. Res. Commun. (1993) 194:811-818.
28. A receptor expressed in Chinese hamster ovary cells. Peptides (1997) 18:865-868.
29. A receptor transduces multiple signals in response to full and partial agonists. Am. J. Physiol. (1993) 265:G999-G1004.
30. YOSHIDA H, TSUNODA Y, OWYANG C: Cholecystokinin peptides stimulate pancreatic secretion by multiple signal transduction pathways. Am. J. Physiol (1997) 273:G735-G747.
31. MARINO CR, LEACH SD, SCHAEFER JF et al.: Characterization of cAMP-dependent protein kinase activation by CCK in rat pancreas. FEBS Lett. (1993) 316:48-52.
32. DUFRESNE M, SEVA C, FOURMY D: Cholecystokinin and gastrin receptors. Physiol. Rev. (2006) 86:805-847.
33. FREIDINGER RM: Cholecystokinin and gastrin antagonists. Med. Res. Rev. (1989) 9:271-290.
34. NADZAN AM, KERWIN JF: Cholecystokinin agonists and antagonists. Ann. Rep. Med. Chem. (1991) 26:191-201.
35. D'AMATO M, ROVATI LC: Cholecystokinin-A receptor antagonists: Therapies for gastrointestinal disorders. Exp. Opin. Invest. Drugs (1997) 6:819-836.
36. DE TULLIO P, DELARGE J, PIROTTE B: Therapeutic and chemical developments of cholecystokinin receptor ligands. Exp. Opin. Invest. Drugs (2000) 9:129-146.
37. KENNEDY K, GIGOUX V. ESCRIEUT C et al.: Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin. J. Biol. Chem. (1997) 272:2920-2926.
38. PELLEGRINI M, MIERKE DF: Molecular complex of cholecystokinin-8 and N terminus of the cholecystokinin A receptor by NMR spectroscopy. Biochemistry (1999) 38:14775-14783.
39. CHANG RS, LOTTI VJ, MONAGHAN RL et al.: A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science (1985) 230:177-179.
40. EVANS BE, RITTLE KE, BOCK MG et al.: Design of nonpeptidal ligands for peptide receptor: cholecystokinin antagonists. J. Med. Chem. (1987) 30:1229-1239.
41. EVANS BE, RITTLE KE, BOCK MG et al.: Methods for drug discovery: development of potent, selective orally effective cholecystokinin antagonists. J. Med. Chem. (1988) 31:2235-2246.
42. WOLTMAN TA, HULCE M, REIDELBERGER RD: Relative blood-brain barrier permeabilties of the cholecystokinin receptor antagonists devazepide and A-65186 in rats. J. Pharm. Pharmacol. (1999) 51:917-920.
43. SATOH Y, MATSUO T, SOGABE H et al.: Studies on a novel, potent and orally effective cholecystokinin A antagonist, FK-480. Synthesis and structure-activity relationships of FK-480 and related compounds. Chem. Pharm. Bull. (Tokyo) (1994) 42:2071-2083.
44. EVANS BE, RITTLE KE, CHANG RSL et al.: Multipurpose receptor ligands: β-carboline cholecystokinin antagonists. Bioorg. Med. Chem. Lett. (1993) 3:867-870
45. FLYNN DL, VILLAMIL CI, BECKER DP et al: 1,3,4-trisubstituted pyrrolidinones as scaffolds for construction of peptidomimeric cholecystokinin antagonists. Bioorg. Med. Chem. Lett. (1992) 2:1251-1256.
46. HOWBERT JJ, LOBB KL, BRITTON TC et al: Diphenylpyrazolidinone and benzodiazepine cholecystokinin antagonists: a case of convergent evolution in medicinal chemistry. Bioorg. Med. Chem. Lett. (1993) 5:875-880.
47. 1 receptor antagonists. Part 1: solution-phase library synthesis and determination of Free-Wilson additivity. Bioorg. Med. Chem. Lett. (2006) 16:72-76.
48. 1 receptor antagonists. Part 2: SAR studies by solid-phase library synthesis and determination of Free-Wilson additivity. Bioorg. Med. Chem. Lett, (2006) 16:77-80.
49. A receptors. Eur. J. Pharmacol. (1993) 232:13-19.
50. A receptor antagonist, in vivo. Eur. J. Pharmacol (1996) 312:227-233.
51. 1 receptor antagonists. Bioorg. Med Chem. (2003) 11:741-751.
52. 1 antagonists: the 2-indole moiety may represent a "needle" according to the recent homonymous concept. Eur. J. Med. Chem. (2004) 39:85-97.
53. 1 receptor antagonists; the final approach. Med. Chem. (2005) 1:501-517
54. 8 have a common step in their "receptor desmodynamic processes". J. Med. Chem. (2006) 49:2456-2462.
55. ROVATI AL, CASULA PL, DA RE G: Pharmacological and experimental toxicology of a new nonanticholinergic product with antisecretory and gastroprotective activity (CR 242, xylamide-Milid). Minerva Med (1967) 58:3656-3670.
56. HAHNE WF, JENSEN RT, LEMP GF et al.: Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonists. Proc. Natl. Acad. Sci. USA (1981) 78:6304-6308.
57. MATON PN, SUTLIFF VE, JENSEN RT et al.: Carbobenzoxy amino acids: structural requirements for cholecystokinin receptor antagonist activity. Am. J Physiol. (1985) 248:G479-G484.
58. MAKOVEC F, CHISTE R, BANI M et al: New glutamic and aspartic derivatives with potent CCK-antagonistic activity. Eur J. Med. Chem. (1986) 21:9-20.
59. MAKOVEC F, BANI M, CEREDA R et al.: Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittel-Forsch. (1987) 37:1265-1268.
60. SETNIKAR I, BANI M, CEREDA R et al: Anticholecystokinin activities of loxiglumide. Arzneimittel-Forsch. (1987) 37:1168-1171.
61. SETNIKAR I, CHISTE R, MAKOVEC F et al: Pharmacokinetics of loxiglumide after single intravenous or oral doses in man. Arzneimittel-Forsch. (1988) 38:716-720.
62. PERSIANI S, D'AMATO M, MAKOVEC F et al.: Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males. Int. J. Clin. Pharmacol. Ther. (2002) 40:198-206.
63. KERWIN JF, NADZAN AM, KOPECKA H et al: Hybrid cholecistokinin (CCK) antagonists: new implications in the design and modification of CCK antagonists. J. Med, Chem. (1989) 32:739-742.
64. FREIDINGER RM, WHITTER WL, GOULD NP et al: Novel glutamic acid derived cholecystokinin receptor ligands. J. Med. Chem. (1990) 33:591-595.
65. YAMAZI Y. AKAHANE M, KOBAYASHI M et al: Pharmacological profile of KSG-504, a new cholecystokinin-A-receptor antagonist. Jpn. J. PharmacoL (1993) 63:219-225.
66. A-receptor antagonist. Br. J. Pharmacol (1993) 108:734-740.
67. AKIYAMA T TACHIBANA I, HIROHATA Y et al: Pharmacological profile of TP-680, a new cholecystokinin A receptor antagonist. Br. J. Pharmacol (1996) 117:1558-1564.
68. TACHIBANA I, KANAGAWA K, YAMAMOTO Y et al.: Pharmacological profile of a new serine derivative cholecystokinin receptor antagonist TP-680 on pancreatic, biliary and gastric function. J. Pharmacol. Exp. Ther. (1996) 279:1404-1412.
69. HORWELL DC, BEEBY A, CLARK CR et al.: Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for CNS cholecystokinin receptors. J. Med. Chem. (1987) 30:729-732.
70. HORWELL DC, BIRCHMORE B, BODEN PR et al.: α-Methyl tryprophanylphenylalanines and their arylethylamine "dipeptoid" analogues of the tetrapeptide cholecystokinin (30-33). Eur. J. Med Chem. (1990) 25:53-60.
71. B antagonists with potent anxiolytic properties. J. Med Chem. (1991) 34:404-414.
72. B antagonists.J. Med. Chem. (1993) 36:552-565.
73. 1 receptor antagonists. J Med. Chem. (2000) 43:3770-3777.
74. 4 analogues incorporating IBTM and BTD β-turn mimetics. J Med Chem. (2005) 48:7667-7674.
75. 4 restricted analogues containing a 3-oxoindolizidine skeleton. Bioorg. Med. Chem. Lett. (1996) 6:967-972.
76. MARTÍN-MARTÍNEZ M, BARTOLOMÉ-NEBREDA JM, GÓMEZ-MONTERREY I et al.: Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]-pyrimidine derivatives: potent and selective cholecystokinin-A receptor antagonists. J. Med. Chem. (1997) 40:3402-3407.
77. A receptor antagonist with anxiolytic-like activity in animal models. Br. J. Pharmacol. (1997) 121:759-767.
78. 1 receptor antagonists: structural modifications at the tryptophan domain. J Med. Chem. (1999) 42:4659-4668.
79. 1 receptor antagonists: structure-activiry relationship studies on the substituent at N2-position. J. Med. Chem. (2001) 44:2219-2228.
80. 1 receptor antagonists: structure-activity relationship studies on the central 1,3-dioxoperhydropyrido-[1,2-c] pyrimidine scaffold. J. Med. Chem (2001) 44:4196-4206.
81. I receptor. J. Med. Chem. (2005) 48:4842-4850.
82. KONTUREK JW, KONTUREK SJ, AKUREK AR et al.: CCK receptor antagonism by loxiglumide and gallbladder contractions response to cholecystokinin, sham feeding and ordinary feeding in man. Gut (1989) 30:1136-1142.
83. MASELLI MA, PIEPOLI AL, PEZZOLLA F et al.: Effect of three nonpeptide cholecystokinin antagonists on human isolated gallbladder. Dig. Dis. Sci, (2001) 46:2773-2778.
84. XU QW, LE MANTLE M, PAULETZKI JG et al.: Sustained gallbladder stasis promotes cholesterol gallstone formation in the ground squirrel. Hepatology (1997) 26:831-836.
85. A receptor gene knockout mice. Dig. Dis. Sci. (2003) 48:1944-1947.
86. KERSTENS PJ, LAMERS CB, JANSEN JB et al.: Physiological plasma concentrations of cholecystokinin stimulate pancreatic enzyme secretion and gallbladder contraction in man. Life Sci. (1985) 36:565-569.
87. WILLIAMS JA.: Intracellular signaling mechanisms activated by cholecystokinin-regulating synthesis and secretion of digestive enzymes in pancreatic acinar cells. Annu. Rev. Physiol. (2001) 63:77-97.
88. OWYANG C, LOGSDON CD: New insights into neurohormonal regulation of pancreatic secretion. Gastroenterology (2004) 127:957-969.
89. REHFELD JF: Cholecystokinin. Best Practice & Research Clin. Endocrinol. & Metabolism (2004) 18:569-586.
90. A receptor antagonists in gastroenterology. DN&P (1994) 7:87-95.
91. HOLLOWAY RH, PENAGINI R, IRELAND AC: Criteria for objective definition of transient lower esophageal sphincter relaxation. Am. J. Physiol. (1995) 268:G128-G138.
92. WYMAN JB, DENT J, HEDDLE R et al.: Control of belching by the lower oesophageal sphincter. Gut (1990) 31:639-646.
93. MITTAL RK, HOLLOWAY RH, PENAGINI R et al.: Transient lower esophageal sphincter relaxation. Gastroenterology (1995) 109:601-61010.
94. BOECKXSTAENS GE, HIRSCH DP, FAKHRY N et al.: Involvement of cholecystokinin A receptors in transient lower esophageal sphincter relaxations triggered by gastric distension. Am. J. Gastroenterol. (1998) 93:182-1828.
95. PARKMAN HP, HASLER WL, FISHER RS: American gastroenterological association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology (2004) 127:1592-1622.
96. TALLEY NJ, VAKIL NB, MOAYYEDI P: American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology (2005) 129:1756-1780.
97. STACHER G, LENGLINGER J, BERGMANN H et al.: Gastric emptying: a contributory factor in gastro-oesophageal reflux activity? Gut (2000) 47:661-666.
98. CHOWDHURY RS, FORSMARK CE, DAVIS RH et al.: Prevalence of gastroparesis in patients with small duct chronic pancreatitis. Pancreas (2003) 26:235-238.
99. SARNELLI G, CAENEPEEL P, GEYPENS B et al.: Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am. J. Gastroenterol. (2003) 98:783-788.
100. LEMANN M, DEDERDING JP, FLOURIE B et al.: Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. Dig. Dis. Sci. (1991) 36:1249-1254.
101. HOLTMANN G: IBS: a syndrome or many diseases? Best Pract. Res. Cl. Ga. (2004) 18:91-97.
102. GILKIN RJ Jr: The spectrum of irritable bowel syndrome: a clinical review. Clin. Ther. (2005) 27:1696-1709.
103. WOODS SC: Signals that influence food intake and body weight. Physiol. Behav. (2005) 86:709-716.
104. STRADER AD, WOODS SC: Gastrointestinal hormones and food intake. Gastroenterology (2005) 128:175-191.
105. A receptor antagonist, stimulates calorie intake and hunger feelings in humans. Am. J. Physiol. (2001) 280:R1149-R1154.
106. KATSCHINSKI M: Drug evaluations: loxiglumide. rotta research. IDrugs (2002) 5:469-474.
107. VARGA G: Dexloxiglumide (Rotta Research Lab). Curr. Opin. Investig. Drugs (2002) 3:621-626.
108. LEE YS, AGNES RS, BADGHISI H et al.: Design and synthesis of novel hydrazide-linked bifunctional peptides as δμ opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J. Med. Chem. (2006) 49:1773-1780.
109. AGNES RS, LEE YS, DAVIS P et al.: Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med. Chem. (2006) 49:2868-2875.